STOCK TITAN

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Wave Life Sciences (Nasdaq: WVE) has announced a virtual Research Day on October 30, 2024, from 10:00 a.m. to 11:30 a.m. ET. The event will showcase the company's progress in RNA medicines, including:

  • Updates on their wholly owned pipeline
  • Introduction of new GalNAc-conjugated RNA editing and siRNA programs
  • Discussion of their clinically validated discovery and drug development platform

The company will highlight WVE-006, their RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), and WVE-007, a GalNAc-siRNA INHBE candidate for obesity treatment. Dr. Mehmet Furkan Burak, an obesity specialist from Harvard Medical School, will provide insights on the current obesity treatment landscape. The event will be accessible via webcast on Wave Life Sciences' investor relations website.

Wave Life Sciences (Nasdaq: WVE) ha annunciato una Giornata di Ricerca virtuale il 30 ottobre 2024, dalle 10:00 alle 11:30 ET. L'evento metterà in mostra i progressi dell'azienda nelle medicine a RNA, tra cui:

  • Aggiornamenti sul loro pipeline interamente di proprietà
  • Introduzione di nuovi programmi di editing RNA e siRNA coniugati a GalNAc
  • Discussione sulla loro piattaforma di scoperta e sviluppo farmaceutico clinicamente valida

L'azienda evidenzierà WVE-006, il loro oligonucleotide per l'editing RNA per la deficienza di alfa-1 antitripsina (AATD), e WVE-007, un candidato GalNAc-siRNA per il trattamento dell'obesità. Il Dr. Mehmet Furkan Burak, specialista in obesità della Harvard Medical School, fornirà approfondimenti sul panorama attuale del trattamento dell'obesità. L'evento sarà accessibile tramite webcast sul sito web delle relazioni con gli investitori di Wave Life Sciences.

Wave Life Sciences (Nasdaq: WVE) ha anunciado un Día de Investigación virtual el 30 de octubre de 2024, de 10:00 a.m. a 11:30 a.m. ET. El evento mostrará los avances de la compañía en medicinas de RNA, incluyendo:

  • Actualizaciones sobre su cartera de medicamentos de propiedad total
  • Introducción de nuevos programas de edición de RNA y siRNA conjugados con GalNAc
  • Discusión sobre su plataforma de descubrimiento y desarrollo de fármacos clínicamente validada

La compañía destacará WVE-006, su oligonucleótido de edición de RNA para la deficiencia de alfa-1 antitripsina (AATD), y WVE-007, un candidato GalNAc-siRNA para el tratamiento de la obesidad. El Dr. Mehmet Furkan Burak, especialista en obesidad de la Harvard Medical School, proporcionará información sobre el panorama actual del tratamiento de la obesidad. El evento será accesible a través de una transmisión web en el sitio de relaciones con inversores de Wave Life Sciences.

Wave Life Sciences (Nasdaq: WVE)는 2024년 10월 30일 오전 10시부터 11시 30분까지 ET에 가상 연구의 날을 발표했습니다. 이 행사는 회사의 RNA 의약품 발전 상황을 소개할 것입니다. 포함된 내용은 다음과 같습니다:

  • 그들의 전적으로 소유한 파이프라인의 업데이트
  • 새로운 GalNAc-결합 RNA 편집 및 siRNA 프로그램의 소개
  • 그들의 임상적으로 검증된 발견 및 약물 개발 플랫폼에 대한 논의

회사는 WVE-006을 강조할 것이며, 이는 알파-1 항트리프신 결핍증(AATD)에 대한 RNA 편집 올리고뉴클레오타이드입니다. 또한 WVE-007, 비만 치료를 위한 GalNAc-siRNA 후보를 소개합니다. 하버드 의대의 비만 전문가인 Mehmet Furkan Burak 박사가 현재 비만 치료 환경에 대한 통찰력을 제공합니다. 이 행사는 Wave Life Sciences의 투자자 관계 웹사이트를 통해 웹캐스트로 접근할 수 있습니다.

Wave Life Sciences (Nasdaq: WVE) a annoncé une Journée de Recherche virtuelle le 30 octobre 2024, de 10 h à 11 h 30 HE. L'événement mettra en avant les progrès de l'entreprise dans les médicaments à ARN, y compris :

  • Mises à jour sur leur pipeline entièrement détenu
  • Introduction de nouveaux programmes de modification de l'ARN et de siRNA conjugués à GalNAc
  • Discussion sur leur plateforme de découverte et de développement de médicaments cliniquement validée

La société mettra en avant WVE-006, son oligonucleotide de modification de l'ARN pour la déficience en alpha-1 antitrypsine (AATD), et WVE-007, un candidat GalNAc-siRNA pour le traitement de l'obésité. Le Dr Mehmet Furkan Burak, spécialiste de l'obésité de la Harvard Medical School, donnera des informations sur le paysage actuel du traitement de l'obésité. L'événement sera accessible par webcast sur le site des relations investisseurs de Wave Life Sciences.

Wave Life Sciences (Nasdaq: WVE) hat einen virtuellen Forschungstag für 30. Oktober 2024 von 10:00 bis 11:30 Uhr ET angekündigt. Die Veranstaltung wird die Fortschritte des Unternehmens in RNA-Medikamenten präsentieren, einschließlich:

  • Aktualisierungen zu ihrer vollständig im eigenen Besitz befindlichen Pipeline
  • Einführung neuer GalNAc-konjugierter RNA-Bearbeitungs- und siRNA-Programme
  • Diskussion über ihre klinisch validierte Entdeckungs- und Arzneimittelentwicklungsplattform

Das Unternehmen wird WVE-006 hervorheben, ihr RNA-Bearbeitungs-Oligonukleotid für Alpha-1-Antitrypsin-Mangel (AATD), sowie WVE-007, einen GalNAc-siRNA INHBE-Kandidaten zur Behandlung von Fettleibigkeit. Dr. Mehmet Furkan Burak, ein Fettleibigkeitsspezialist von der Harvard Medical School, wird Einblicke in die aktuelle Behandlungslage von Fettleibigkeit geben. Die Veranstaltung wird über einen Webcast auf der Investor-Relations-Website von Wave Life Sciences zugänglich sein.

Positive
  • None.
Negative
  • None.

Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity

CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced it will host a virtual Research Day on Wednesday, October 30, 2024 at 10:00 a.m. ET (until 11:30 a.m. ET).

During the event, Wave will provide an update on its rapidly advancing, wholly owned pipeline, introduce new GalNAc-conjugated RNA editing and siRNA programs, and discuss its clinically validated discovery and drug development platform, including its novel chemistry innovations enabling best-in-class potency, durability and delivery. The new RNA editing programs build on the learnings of WVE-006, Wave’s GalNAc-conjugated RNA editing oligonucleotide being advanced in the clinic for the treatment of alpha-1 antitrypsin deficiency – the first ADAR editing therapeutic to enter clinical development.

Wave will also highlight the opportunity for WVE-007, Wave’s GalNAc-siRNA INHBE candidate, as a novel obesity treatment, share new preclinical data, and discuss the differentiated profile of WVE-007. The event will feature perspectives from a key opinion leader in obesity, Mehmet Furkan Burak, MD, who will discuss the current treatment landscape for obesity and the unmet needs that remain. Dr. Burak is an Instructor in Medicine at Harvard Medical School (Endocrinology, Diabetes, and Hypertension) and an endocrinologist and obesity specialist at Brigham and Women's Hospital Center for Weight Management and Wellness.

Wave’s Virtual Research Day
A webcast of the event can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the event can join the audio-conferencing link available here. Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.  

Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com


FAQ

When is Wave Life Sciences hosting its virtual Research Day?

Wave Life Sciences is hosting its virtual Research Day on Wednesday, October 30, 2024, from 10:00 a.m. to 11:30 a.m. ET.

What will be discussed during Wave Life Sciences' Research Day?

The Research Day will cover updates on Wave's wholly owned pipeline, new GalNAc-conjugated RNA editing and siRNA programs, their drug development platform, WVE-006 for AATD, and WVE-007 for obesity treatment.

What is WVE-006 being developed for?

WVE-006 is being developed as an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency (AATD).

What is Wave Life Sciences' WVE-007 targeting?

WVE-007 is a GalNAc-siRNA INHBE candidate being developed as a novel treatment for obesity.

Who is the key opinion leader speaking at Wave's Research Day?

Dr. Mehmet Furkan Burak, an Instructor in Medicine at Harvard Medical School and an endocrinologist and obesity specialist at Brigham and Women's Hospital, will discuss the current obesity treatment landscape.

Wave Life Sciences Ltd. Ordinary Shares

NASDAQ:WVE

WVE Rankings

WVE Latest News

WVE Stock Data

2.10B
151.66M
15.79%
64.76%
3.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SINGAPORE